Loading…

Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission

To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first co...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2012-06, Vol.97 (6), p.915-918
Main Authors: YANADA, Masamitsu, KUROSAWA, Saiko, TAKAMATSU, Yasushi, WAKI, Fusako, YOKOYAMA, Hiroki, WATANABE, Masato, EMI, Nobuhiko, FUKUDA, Takahiro, YAMAGUCHI, Takuhiro, YAMASHITA, Takuya, MORIUCHI, Yukiyoshi, AGO, Hiroatsu, TAKEUCHI, Jin, NAKAMAE, Hirohisa, TAGUCHI, Jun, SAKURA, Toru
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963
cites
container_end_page 918
container_issue 6
container_start_page 915
container_title Haematologica (Roma)
container_volume 97
creator YANADA, Masamitsu
KUROSAWA, Saiko
TAKAMATSU, Yasushi
WAKI, Fusako
YOKOYAMA, Hiroki
WATANABE, Masato
EMI, Nobuhiko
FUKUDA, Takahiro
YAMAGUCHI, Takuhiro
YAMASHITA, Takuya
MORIUCHI, Yukiyoshi
AGO, Hiroatsu
TAKEUCHI, Jin
NAKAMAE, Hirohisa
TAGUCHI, Jun
SAKURA, Toru
description To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.
doi_str_mv 10.3324/haematol.2011.058289
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_00d5db78d75f4be993138f6bb3fd79d1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_00d5db78d75f4be993138f6bb3fd79d1</doaj_id><sourcerecordid>1018863508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963</originalsourceid><addsrcrecordid>eNpVks1u1DAUhSMEoqXwBgh5g8RmBjuOE3uDhCp-KlWCBaytG-cmcevEwfZ0NC_G8-H5aUtXlu3vHp97fYriLaNrzsvq4wg4QfJuXVLG1lTIUqpnxTkTqlzJpmTPi3PKFV3VtJFnxasYbygtqVLNy-KsLJmkFWfnxd-fwQ-zjzYS3xMwm4Rk2qHztiMON7c4WSAjhNYHOw9k8pn1EzhyC2Hn025BYmeyQLI4p0hSQEjYka1NI_HhsPpNIuCcH3BGa8h4sL14iynvDDqXq2COi4M5ZR0_E-gThmxmtHi3f9X4aXGYnYVsJ8aMvC5e9OAivjmtF8Xvr19-XX5fXf_4dnX5-XplBK_SigMtGVfQiKovUUjRIGemN8hEw0sQXNBKVHUtepBCdkqJBphRitW0y9uaXxRXR93Ow41egp1y29qD1YcDHwYNIffhUFPaia5tZNeIvmpRKc647Ou25X3XqI5lrU9HrWXTTtiZPLAA7ono05vZjnrwd5rzOltUWeDDSSD4PxuMSedp7AcIM_pN1IwyKevck8xodURN8DEG7B-eYVTv46Pv46P38dHH-OSyd_9bfCi6z0sG3p8AiAZcnz_O2PjI1VQwKqtHbrTDuLUBdcyhcVm21NvtVjW61ooJ_g-2HeO5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018863508</pqid></control><display><type>article</type><title>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</title><source>PubMed Central Free</source><source>Freely Accessible Science Journals - check A-Z of ejournals</source><creator>YANADA, Masamitsu ; KUROSAWA, Saiko ; TAKAMATSU, Yasushi ; WAKI, Fusako ; YOKOYAMA, Hiroki ; WATANABE, Masato ; EMI, Nobuhiko ; FUKUDA, Takahiro ; YAMAGUCHI, Takuhiro ; YAMASHITA, Takuya ; MORIUCHI, Yukiyoshi ; AGO, Hiroatsu ; TAKEUCHI, Jin ; NAKAMAE, Hirohisa ; TAGUCHI, Jun ; SAKURA, Toru</creator><creatorcontrib>YANADA, Masamitsu ; KUROSAWA, Saiko ; TAKAMATSU, Yasushi ; WAKI, Fusako ; YOKOYAMA, Hiroki ; WATANABE, Masato ; EMI, Nobuhiko ; FUKUDA, Takahiro ; YAMAGUCHI, Takuhiro ; YAMASHITA, Takuya ; MORIUCHI, Yukiyoshi ; AGO, Hiroatsu ; TAKEUCHI, Jin ; NAKAMAE, Hirohisa ; TAGUCHI, Jun ; SAKURA, Toru</creatorcontrib><description>To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.</description><identifier>ISSN: 0390-6078</identifier><identifier>EISSN: 1592-8721</identifier><identifier>DOI: 10.3324/haematol.2011.058289</identifier><identifier>PMID: 22180431</identifier><language>eng</language><publisher>Pavia: Ferrata Storti Foundation</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents - administration &amp; dosage ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Chromosome aberrations ; Female ; Hematologic and hematopoietic diseases ; Hematopoietic Stem Cell Transplantation ; Humans ; Karyotyping ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - mortality ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical genetics ; Medical sciences ; Middle Aged ; Monosomy - diagnosis ; Monosomy - genetics ; Original and Brief Reports ; Recurrence ; Remission Induction ; Retrospective Studies ; Survival Rate ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Haematologica (Roma), 2012-06, Vol.97 (6), p.915-918</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright© Ferrata Storti Foundation 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366659/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366659/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26051084$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22180431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YANADA, Masamitsu</creatorcontrib><creatorcontrib>KUROSAWA, Saiko</creatorcontrib><creatorcontrib>TAKAMATSU, Yasushi</creatorcontrib><creatorcontrib>WAKI, Fusako</creatorcontrib><creatorcontrib>YOKOYAMA, Hiroki</creatorcontrib><creatorcontrib>WATANABE, Masato</creatorcontrib><creatorcontrib>EMI, Nobuhiko</creatorcontrib><creatorcontrib>FUKUDA, Takahiro</creatorcontrib><creatorcontrib>YAMAGUCHI, Takuhiro</creatorcontrib><creatorcontrib>YAMASHITA, Takuya</creatorcontrib><creatorcontrib>MORIUCHI, Yukiyoshi</creatorcontrib><creatorcontrib>AGO, Hiroatsu</creatorcontrib><creatorcontrib>TAKEUCHI, Jin</creatorcontrib><creatorcontrib>NAKAMAE, Hirohisa</creatorcontrib><creatorcontrib>TAGUCHI, Jun</creatorcontrib><creatorcontrib>SAKURA, Toru</creatorcontrib><title>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chromosome aberrations</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Karyotyping</subject><subject>Leukemia, Myeloid, Acute - diagnosis</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monosomy - diagnosis</subject><subject>Monosomy - genetics</subject><subject>Original and Brief Reports</subject><subject>Recurrence</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>0390-6078</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVks1u1DAUhSMEoqXwBgh5g8RmBjuOE3uDhCp-KlWCBaytG-cmcevEwfZ0NC_G8-H5aUtXlu3vHp97fYriLaNrzsvq4wg4QfJuXVLG1lTIUqpnxTkTqlzJpmTPi3PKFV3VtJFnxasYbygtqVLNy-KsLJmkFWfnxd-fwQ-zjzYS3xMwm4Rk2qHztiMON7c4WSAjhNYHOw9k8pn1EzhyC2Hn025BYmeyQLI4p0hSQEjYka1NI_HhsPpNIuCcH3BGa8h4sL14iynvDDqXq2COi4M5ZR0_E-gThmxmtHi3f9X4aXGYnYVsJ8aMvC5e9OAivjmtF8Xvr19-XX5fXf_4dnX5-XplBK_SigMtGVfQiKovUUjRIGemN8hEw0sQXNBKVHUtepBCdkqJBphRitW0y9uaXxRXR93Ow41egp1y29qD1YcDHwYNIffhUFPaia5tZNeIvmpRKc647Ou25X3XqI5lrU9HrWXTTtiZPLAA7ono05vZjnrwd5rzOltUWeDDSSD4PxuMSedp7AcIM_pN1IwyKevck8xodURN8DEG7B-eYVTv46Pv46P38dHH-OSyd_9bfCi6z0sG3p8AiAZcnz_O2PjI1VQwKqtHbrTDuLUBdcyhcVm21NvtVjW61ooJ_g-2HeO5</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>YANADA, Masamitsu</creator><creator>KUROSAWA, Saiko</creator><creator>TAKAMATSU, Yasushi</creator><creator>WAKI, Fusako</creator><creator>YOKOYAMA, Hiroki</creator><creator>WATANABE, Masato</creator><creator>EMI, Nobuhiko</creator><creator>FUKUDA, Takahiro</creator><creator>YAMAGUCHI, Takuhiro</creator><creator>YAMASHITA, Takuya</creator><creator>MORIUCHI, Yukiyoshi</creator><creator>AGO, Hiroatsu</creator><creator>TAKEUCHI, Jin</creator><creator>NAKAMAE, Hirohisa</creator><creator>TAGUCHI, Jun</creator><creator>SAKURA, Toru</creator><general>Ferrata Storti Foundation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120601</creationdate><title>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</title><author>YANADA, Masamitsu ; KUROSAWA, Saiko ; TAKAMATSU, Yasushi ; WAKI, Fusako ; YOKOYAMA, Hiroki ; WATANABE, Masato ; EMI, Nobuhiko ; FUKUDA, Takahiro ; YAMAGUCHI, Takuhiro ; YAMASHITA, Takuya ; MORIUCHI, Yukiyoshi ; AGO, Hiroatsu ; TAKEUCHI, Jin ; NAKAMAE, Hirohisa ; TAGUCHI, Jun ; SAKURA, Toru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chromosome aberrations</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Karyotyping</topic><topic>Leukemia, Myeloid, Acute - diagnosis</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monosomy - diagnosis</topic><topic>Monosomy - genetics</topic><topic>Original and Brief Reports</topic><topic>Recurrence</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YANADA, Masamitsu</creatorcontrib><creatorcontrib>KUROSAWA, Saiko</creatorcontrib><creatorcontrib>TAKAMATSU, Yasushi</creatorcontrib><creatorcontrib>WAKI, Fusako</creatorcontrib><creatorcontrib>YOKOYAMA, Hiroki</creatorcontrib><creatorcontrib>WATANABE, Masato</creatorcontrib><creatorcontrib>EMI, Nobuhiko</creatorcontrib><creatorcontrib>FUKUDA, Takahiro</creatorcontrib><creatorcontrib>YAMAGUCHI, Takuhiro</creatorcontrib><creatorcontrib>YAMASHITA, Takuya</creatorcontrib><creatorcontrib>MORIUCHI, Yukiyoshi</creatorcontrib><creatorcontrib>AGO, Hiroatsu</creatorcontrib><creatorcontrib>TAKEUCHI, Jin</creatorcontrib><creatorcontrib>NAKAMAE, Hirohisa</creatorcontrib><creatorcontrib>TAGUCHI, Jun</creatorcontrib><creatorcontrib>SAKURA, Toru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YANADA, Masamitsu</au><au>KUROSAWA, Saiko</au><au>TAKAMATSU, Yasushi</au><au>WAKI, Fusako</au><au>YOKOYAMA, Hiroki</au><au>WATANABE, Masato</au><au>EMI, Nobuhiko</au><au>FUKUDA, Takahiro</au><au>YAMAGUCHI, Takuhiro</au><au>YAMASHITA, Takuya</au><au>MORIUCHI, Yukiyoshi</au><au>AGO, Hiroatsu</au><au>TAKEUCHI, Jin</au><au>NAKAMAE, Hirohisa</au><au>TAGUCHI, Jun</au><au>SAKURA, Toru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>97</volume><issue>6</issue><spage>915</spage><epage>918</epage><pages>915-918</pages><issn>0390-6078</issn><eissn>1592-8721</eissn><abstract>To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.</abstract><cop>Pavia</cop><pub>Ferrata Storti Foundation</pub><pmid>22180431</pmid><doi>10.3324/haematol.2011.058289</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0390-6078
ispartof Haematologica (Roma), 2012-06, Vol.97 (6), p.915-918
issn 0390-6078
1592-8721
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_00d5db78d75f4be993138f6bb3fd79d1
source PubMed Central Free; Freely Accessible Science Journals - check A-Z of ejournals
subjects Adolescent
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Chromosome aberrations
Female
Hematologic and hematopoietic diseases
Hematopoietic Stem Cell Transplantation
Humans
Karyotyping
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical genetics
Medical sciences
Middle Aged
Monosomy - diagnosis
Monosomy - genetics
Original and Brief Reports
Recurrence
Remission Induction
Retrospective Studies
Survival Rate
Transplantation, Homologous
Treatment Outcome
title Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A29%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20of%20acute%20myeloid%20leukemia%20harboring%20monosomal%20karyotype%20in%20patients%20treated%20with%20or%20without%20allogeneic%20hematopoietic%20cell%20transplantation%20after%20achieving%20complete%20remission&rft.jtitle=Haematologica%20(Roma)&rft.au=YANADA,%20Masamitsu&rft.date=2012-06-01&rft.volume=97&rft.issue=6&rft.spage=915&rft.epage=918&rft.pages=915-918&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/10.3324/haematol.2011.058289&rft_dat=%3Cproquest_doaj_%3E1018863508%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c534t-3a02139a754f2e5857e31cfce15732a5350454665fa858d9957a1c99160d8d963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1018863508&rft_id=info:pmid/22180431&rfr_iscdi=true